| 摘要 |
PROBLEM TO BE SOLVED: To provide an OATP-R gene expression-enhancing composition that ensures higher safety and exhibits an OATP-R gene expression-enhancing action. SOLUTION: The OATP-R gene expression-enhancing composition comprises an angiotensin II receptor-inhibiting substance (ARB) and/or a glitazone-based hypoglycemic substance. As the ARB, there can be preferably exemplified losartan, candesartan, candesartan cilexetil, olmesartan, valsartan, irbesartan, eprosartan, telmisartan, EXP3174 (a metabolite of losartan), and RNH6270 (an olmesartan activator). As the glitazone hypoglycemic substance, there can be preferably exemplified pioglitazone, troglitazone, rosiglitazone, and rosiglitazone maleate. COPYRIGHT: (C)2011,JPO&INPIT
|
